Cargando…

Amisulpride Augmentation in Schizophrenia Patients with Poor Response to Olanzapine: A 4-week, Randomized, Rater-Blind, Controlled, Pilot Study

OBJECTIVE: The purpose of this study was to compare the efficacy and tolerability of continued olanzapine (OLA) versus amisulpride (AMI) augmentation in schizophrenic patients with poor response to OLA monotherapy. METHODS: The present 4-week, randomized, rater-blinded study included 25 patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Woo, Young Sup, Park, Sung-Yong, Yoon, Bo-Hyun, Choi, Won-Seok, Wang, Sheng-Min, Bahk, Won-Myong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean College of Neuropsychopharmacology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329105/
https://www.ncbi.nlm.nih.gov/pubmed/35879041
http://dx.doi.org/10.9758/cpn.2022.20.3.567
_version_ 1784757866308042752
author Woo, Young Sup
Park, Sung-Yong
Yoon, Bo-Hyun
Choi, Won-Seok
Wang, Sheng-Min
Bahk, Won-Myong
author_facet Woo, Young Sup
Park, Sung-Yong
Yoon, Bo-Hyun
Choi, Won-Seok
Wang, Sheng-Min
Bahk, Won-Myong
author_sort Woo, Young Sup
collection PubMed
description OBJECTIVE: The purpose of this study was to compare the efficacy and tolerability of continued olanzapine (OLA) versus amisulpride (AMI) augmentation in schizophrenic patients with poor response to OLA monotherapy. METHODS: The present 4-week, randomized, rater-blinded study included 25 patients with schizophrenia who were partially or completely unresponsive to treatment with OLA monotherapy. Eligible subjects were randomly assigned at a 11 ratio to continuation of OLA monotherapy (OLA group) or OLA with AMI augmentation (AMI group). Efficacy was primarily evaluated using the Positive and Negative Syndrome Scale (PANSS) at baseline and at 1, 2, and 4 weeks. RESULTS: The changes in PANSS total score and PANSS-positive subscale score were significantly different (p < 0.05) between the OLA and AMI groups. The differences between the two groups in PANSS-negative subscale, PANSS-general subscale, Brief Psychiatric Rating Scale, and Clinical Global Impression-Severity (CGI-S) scale scores were not statistically significant. CONCLUSION: AMI augmentation could be an effective strategy for patients with schizophrenia who show inadequate early response to OLA monotherapy.
format Online
Article
Text
id pubmed-9329105
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Korean College of Neuropsychopharmacology
record_format MEDLINE/PubMed
spelling pubmed-93291052022-08-31 Amisulpride Augmentation in Schizophrenia Patients with Poor Response to Olanzapine: A 4-week, Randomized, Rater-Blind, Controlled, Pilot Study Woo, Young Sup Park, Sung-Yong Yoon, Bo-Hyun Choi, Won-Seok Wang, Sheng-Min Bahk, Won-Myong Clin Psychopharmacol Neurosci Brief Report OBJECTIVE: The purpose of this study was to compare the efficacy and tolerability of continued olanzapine (OLA) versus amisulpride (AMI) augmentation in schizophrenic patients with poor response to OLA monotherapy. METHODS: The present 4-week, randomized, rater-blinded study included 25 patients with schizophrenia who were partially or completely unresponsive to treatment with OLA monotherapy. Eligible subjects were randomly assigned at a 11 ratio to continuation of OLA monotherapy (OLA group) or OLA with AMI augmentation (AMI group). Efficacy was primarily evaluated using the Positive and Negative Syndrome Scale (PANSS) at baseline and at 1, 2, and 4 weeks. RESULTS: The changes in PANSS total score and PANSS-positive subscale score were significantly different (p < 0.05) between the OLA and AMI groups. The differences between the two groups in PANSS-negative subscale, PANSS-general subscale, Brief Psychiatric Rating Scale, and Clinical Global Impression-Severity (CGI-S) scale scores were not statistically significant. CONCLUSION: AMI augmentation could be an effective strategy for patients with schizophrenia who show inadequate early response to OLA monotherapy. Korean College of Neuropsychopharmacology 2022-08-31 2022-08-31 /pmc/articles/PMC9329105/ /pubmed/35879041 http://dx.doi.org/10.9758/cpn.2022.20.3.567 Text en Copyright© 2022, Korean College of Neuropsychopharmacology https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Brief Report
Woo, Young Sup
Park, Sung-Yong
Yoon, Bo-Hyun
Choi, Won-Seok
Wang, Sheng-Min
Bahk, Won-Myong
Amisulpride Augmentation in Schizophrenia Patients with Poor Response to Olanzapine: A 4-week, Randomized, Rater-Blind, Controlled, Pilot Study
title Amisulpride Augmentation in Schizophrenia Patients with Poor Response to Olanzapine: A 4-week, Randomized, Rater-Blind, Controlled, Pilot Study
title_full Amisulpride Augmentation in Schizophrenia Patients with Poor Response to Olanzapine: A 4-week, Randomized, Rater-Blind, Controlled, Pilot Study
title_fullStr Amisulpride Augmentation in Schizophrenia Patients with Poor Response to Olanzapine: A 4-week, Randomized, Rater-Blind, Controlled, Pilot Study
title_full_unstemmed Amisulpride Augmentation in Schizophrenia Patients with Poor Response to Olanzapine: A 4-week, Randomized, Rater-Blind, Controlled, Pilot Study
title_short Amisulpride Augmentation in Schizophrenia Patients with Poor Response to Olanzapine: A 4-week, Randomized, Rater-Blind, Controlled, Pilot Study
title_sort amisulpride augmentation in schizophrenia patients with poor response to olanzapine: a 4-week, randomized, rater-blind, controlled, pilot study
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329105/
https://www.ncbi.nlm.nih.gov/pubmed/35879041
http://dx.doi.org/10.9758/cpn.2022.20.3.567
work_keys_str_mv AT wooyoungsup amisulprideaugmentationinschizophreniapatientswithpoorresponsetoolanzapinea4weekrandomizedraterblindcontrolledpilotstudy
AT parksungyong amisulprideaugmentationinschizophreniapatientswithpoorresponsetoolanzapinea4weekrandomizedraterblindcontrolledpilotstudy
AT yoonbohyun amisulprideaugmentationinschizophreniapatientswithpoorresponsetoolanzapinea4weekrandomizedraterblindcontrolledpilotstudy
AT choiwonseok amisulprideaugmentationinschizophreniapatientswithpoorresponsetoolanzapinea4weekrandomizedraterblindcontrolledpilotstudy
AT wangshengmin amisulprideaugmentationinschizophreniapatientswithpoorresponsetoolanzapinea4weekrandomizedraterblindcontrolledpilotstudy
AT bahkwonmyong amisulprideaugmentationinschizophreniapatientswithpoorresponsetoolanzapinea4weekrandomizedraterblindcontrolledpilotstudy